A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Recruiting

Phase 1

ElecoglipronA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Sponsor:

AstraZeneca

Code:

NCT07723833

Conditions

Healthy Participants

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Elecoglipron Reference Formulation Dose A

Elecoglipron Test formulation 1 Dose A

Elecoglipron Reference Formulation Dose B

Elecoglipron Test formulation 1 Dose B

Elecoglipron Test formulation 2 Dose A

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-19. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-08-03.